Enlight Medical has partnered with Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, to accelerates commercial availability of Seer’s Proteograph Product Suite to the rapidly expanding Chinese life sciences and clinical markets.

Through the partnership, Enlight’s experienced team will manage sales, marketing, and customer service for Seer’s Proteograph Product Suite and pave the way for expanding access to this disruptive platform in China. The Proteograph Product Suite, which leverages Seer’s proprietary engineered nanoparticle technology, empowers scientists and clinicians to obtain a clearer view of biology by enabling unbiased, deep access to the proteome at a scale never before possible.

About Seer Bio

Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer is commercializing its Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

contact Sales@enlight-medical.com for business in the Greater China region